VEGFA and neoplasm: Liver (HepG2), lung (A549), and colorectal (SW620) vasculature‐on‐a‐chip cancer models were effective in testing VEGF‐ and VEGFR‐targeting siRNA‐mesoporous silica NPs (MSNs) as targeted anti‐angiogenesis therapeutics.[80] siVEGFR/MSN was found to have a greater anti‐angiogenic influence on the ToCs and inhibited tumor growth, thus demonstrating high targeted delivery of the targeted therapeutic agent siVEGFR using MSN.[80] These results were validated in animal models[80] indicating CoC accuracy as a preclinical platform for TCT development and testing.